Keyphrases
COVID-19
100%
Indonesia
66%
Surabaya
59%
COVID-19 Patients
57%
Systematic Meta-analysis
38%
Meta-analysis
33%
AIDS/HIV
30%
Human Immunodeficiency Virus Type 1 (HIV-1)
16%
Hydroxychloroquine
16%
Interleukin-6
15%
Mortality Prediction
13%
Indonesian
13%
Intensive Care Unit
12%
Chronic Obstructive Pulmonary Disease
12%
Antiretroviral Therapy
12%
Bronchodilator
11%
Neutrophil-to-lymphocyte Ratio
11%
Antibiotics
11%
D-dimer
11%
Core Needle Biopsy
11%
Lung Tissue
10%
Lopinavir
10%
Clinical Impact
10%
Platform Trials
10%
Drug Combination
10%
Stakeholder Collaboration
10%
Referral Hospital
10%
Healthcare Stakeholders
10%
Human Immunodeficiency Virus Drug Resistance
10%
COVID-19 Mortality
10%
Monotherapy
10%
Interleukin-17 (IL-17)
9%
Brixia Score
9%
Antiviral Activity
9%
Neutrophil Count
9%
Azithromycin
9%
Drug Resistance mutations
9%
CRF01_AE
9%
Lymphocytes
9%
Clinical Outcomes
9%
Asthma
9%
Neutrophil-lymphocyte Ratio
9%
MT-4 Cells
9%
Bronchodilator Therapy
9%
Human Immunodeficiency Virus Infection
8%
Krebs Von Den Lungen-6 (KL-6)
8%
Academic Hospital
8%
Randomized Controlled Trial
8%
Tocilizumab
7%
COVID-19 Severity
7%
Risk Ratio
7%
Asthma Management
7%
Disease Severity
7%
East Java
7%
Doxycycline
7%
Pneumonia
7%
Length of Hospital Stay
7%
Hospital Performance
7%
Performance Factor
7%
Weight Gain
7%
Usual Care
7%
Asthma Symptoms
7%
Antibiotic Use
7%
Interleukin-10
7%
Hypertension
7%
Human Immunodeficiency Virus/acquired Immunodeficiency Syndrome
7%
Hospitalized Patients
6%
East Java Indonesia
6%
Pathological Findings
6%
Chronic Hepatitis B
6%
Pulmonary Tuberculosis
6%
COVID-19 Infection
6%
Acute Exacerbation of COPD (AECOPD)
6%
Bacterial Infection
6%
IC50
6%
Critically Ill COVID-19 Patients
6%
High Dose
6%
Anticoagulants
6%
Chest X-ray
6%
Critical COVID-19
6%
Treatment Outcome
6%
Valproic Acid
6%
Hospital Mortality
6%
Human Immunodeficiency Virus Patients
6%
Tuberculosis
6%
COVID-19 Treatment
6%
In Vitro Study
6%
Empiric Antibiotics
6%
Tumor Necrosis Factor-α
6%
Coagulopathy
6%
Moderate to Severe
5%
COVID-19 Vaccine
5%
Dual Drug
5%
Moderate COVID-19
5%
Regional Public Hospital
5%
Type Distribution
5%
Neutrophils
5%
Interleukin-6 Expression
5%
Asthma Patients
5%
Prevention Programs
5%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
59%
HIV
47%
Coronavirinae
36%
Infection
28%
SARS Coronavirus
25%
Antivirus Agent
23%
Drug Resistance
21%
Interleukin 6
19%
Asthma
18%
Candida
16%
Hydroxychloroquine
16%
Prevalence
15%
Cross-Sectional Study
14%
Retrospective Study
13%
Bronchodilating Agent
11%
Lopinavir Plus Ritonavir
10%
Combination Drug
10%
Hospital Mortality
10%
Chronic Obstructive Lung Disease
10%
Gelatinase B
10%
Nystatin
10%
Thrush
10%
Lung Tuberculosis
10%
Adverse Event
10%
Randomized Controlled Trial
10%
Azithromycin
9%
Monotherapy
9%
D Dimer
9%
Antiviral Activity
8%
Biological Marker
8%
Human Immunodeficiency Virus 1
8%
Molnupiravir
8%
Antibiotics
7%
Candida Albicans
7%
Disease Severity
7%
Doxycycline
7%
Mixed Infection
7%
Placebo
7%
Infectious Agent
6%
Antibiotic Prophylaxis
6%
Bacterial Infection
6%
Bloodstream Infection
6%
C Reactive Protein
6%
Fibrosis
6%
IC50
6%
Antioxidant
6%
Anticoagulant Agent
6%
Tocilizumab
6%
Antifungal Therapy
6%
Sodium Valproate
6%
Resistance to Antifungal Agent
5%
COVID-19 Vaccine
5%
Gram Negative Bacterium
5%
Antiviral Drug
5%
Diabetes Mellitus
5%
CYP2C19
5%
Leptin
5%
Alpinia
5%
Empagliflozin
5%
Lung Injury
5%
Lacunar Stroke
5%
Antibiotic Therapy
5%
Blood Clotting Disorder
5%
Lung Edema
5%
Hepatitis B(e) Antigen
5%
Interleukin 17
5%
Tissue Inhibitor of Metalloproteinase
5%
Metalloproteinase Inhibitor
5%
RNA
5%
Syndrome
5%
Adiponectin
5%
Ischemic Heart Disease
5%
Lung Infiltrate
5%
Valproate Semisodium
5%
Tuberculous Meningitis
5%
Quantum Dot
5%
Clinical Study
5%
Integrase
5%
Prognosis
5%
Tuberculous Pleurisy
5%
Lactate Dehydrogenase
5%
Carbon Quantum Dot
5%
Chronic Hepatitis B
5%
Case-Control Study
5%
Chloroquine
5%
Heart Disease
5%
Survival Prediction
5%
Acquired Immune Deficiency Syndrome
5%
Leukocyte Elastase
5%
Ocimum Sanctum Extract
5%
Rosemary
5%
Basil
5%
Eugenol
5%
Vagina Candidiasis
5%
Antifungal Activity
5%
Psoriasis Vulgaris
5%
Fungemia
5%
Mycobacterium Tuberculosis
5%
Antimicrobial Resistance
5%
Medicine and Dentistry
COVID-19
74%
Systematic Review
16%
Lymphocyte
16%
Human Immunodeficiency Virus 1
14%
Retrospective Study
12%
Meta-Analysis
12%
Human Immunodeficiency Virus
11%
Asthma
11%
Biopsy Technique
11%
Antibiotic Therapy
10%
Drug Megadose
10%
Mixed Infection
10%
Drug Resistance
10%
Neutrophil
10%
Lung Tuberculosis
10%
Mycobacterium Tuberculosis
10%
Infection
9%
Intensive Care Unit
9%
Diseases
9%
Cross Sectional Study
9%
D-Dimer
8%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Low Drug Dose
7%
Interleukin 6
7%
Prevalence
7%
Lung
7%
Antiretroviral Therapy
6%
Antibiotic Prophylaxis
6%
Sputum
6%
Disease Severity
6%
Hemodynamic
6%
Patient Referral
6%
Diagnosis
5%
Gram-Negative Bacteria
5%
Microvessel
5%
Melanoma Antigen
5%
COVID-19 Vaccine
5%
Hydroxychloroquine
5%
Chloroquine
5%
Immunohistochemistry
5%
Meta-Regression
5%
Empagliflozin
5%
Chronic Kidney Disease
5%
T-Helper Cell
5%
Lacunar Stroke
5%
COVID-19 Therapy
5%
Systematic Review with Meta-Analysis
5%
Omicron Coronavirus Variant
5%
Nonalcoholic Fatty Liver
5%
Interleukin 17
5%
Pulmonary Edema
5%
Hospital Mortality
5%
Tumor Necrosis Factor
5%
RNA
5%
CYP2C19
5%
Adjuvant Therapy
5%
Valproate Semisodium
5%
Chest Radiograph
5%
Pulmonary Infiltrate
5%
Pathogen
5%
Tuberculous Meningitis
5%
Placebo
5%
Lung Tumor
5%
Feces
5%
Ozone Therapy
5%
SARS Coronavirus
5%
Needs Assessment
5%
Plasmodium Vivax Malaria
5%
COVID-19 Mortality
5%
Screening Test
5%
Pleurodesis
5%
Hospital Management
5%
Metabolic Syndrome
5%
Malignant Pleural Effusion
5%
Helicobacter Pylori
5%
Stomach Biopsy
5%
Acquired Immune Deficiency Syndrome
5%
Systemic Lupus Erythematosus
5%
Digital Imaging
5%
Tuberculous Pleurisy
5%
Lupus Nephritis
5%
Intracardiac Thrombosis
5%
Tolonium Chloride
5%
Vagina Candidiasis
5%
Psoriasis Vulgaris
5%
Bloodstream Infection
5%
Antibiotic Resistance
5%
Tuberculosis Diagnosis
5%